Sarcoma management demands coordinated, subtype-specific care and treatment sensitivities delivered by a dedicated multidisciplinary team.
Related to this article
Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma, a cancer with few treatment options, to identify new treatment vulnerabilities.
Ris-rez improved PFS vs chemotherapy in the ARTEMIS-011 trial for relapsed/refractory osteosarcoma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Mulvey on Real-World Treatment Discontinuation Data for First-Line BTK Inhibitors in CLL
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Dr Cohen on Phase 1 Efficacy Data for Cevostamab in R/R Myeloma
4
Docirbrutinib Yields High Response Rates in MCL and CLL
5